Tirzepatide is a dual GIP/GLP-1 receptor agonist investigated for glycaemic regulation, insulin sensitivity, body weight management, and metabolic syndrome research.
| Molecular Weight | 4813.51 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Tirzepatide is a synthetic peptide that acts as a dual agonist for the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and the Glucagon-like Peptide-1 (GLP-1) receptor. It is often referred to as a "twincretin" because it targets these two key incretin hormones simultaneously.
By activating both GIP and GLP-1 receptors, Tirzepatide produces a synergistic effect on metabolic health. GLP-1 primarily acts on appetite suppression and insulin secretion, while GIP improves insulin sensitivity and may protect against some of the gastrointestinal side effects associated with pure GLP-1 agonists. This dual action leads to superior blood sugar control and weight loss compared to single-receptor agonists.
Tirzepatide is currently the subject of intense research for its unprecedented efficacy in weight loss—with studies showing up to 22.5% body weight reduction. It is also being investigated for its impact on cardiovascular health, non-alcoholic fatty liver disease (NAFLD), and its potential to reverse Type 2 diabetes in research models.